Wolverine Asset Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.1M | Sell |
18,600
-200
| -1% | -$203K | 0.16% | 135 |
|
|
2025
Q4 | $20.2M | Sell |
18,800
-11,500
| -38% | -$11M | 0.16% | 155 |
|
|
2025
Q3 | $23.1M | Sell |
30,300
-1,000
| -3% | -$744K | 0.17% | 131 |
|
|
2025
Q2 | $24.4M | Buy |
31,300
+21,600
| +223% | +$16.8M | 0.23% | 109 |
|
|
2025
Q1 | $8.01M | Buy |
9,700
+6,800
| +234% | +$5.66M | 0.1% | 224 |
|
|
2024
Q4 | $2.24M | Sell |
2,900
-3,400
| -54% | -$2.82M | 0.02% | 506 |
|
|
2024
Q3 | $5.58M | Sell |
6,300
-3,000
| -32% | -$2.7M | 0.06% | 285 |
|
|
2024
Q2 | $8.42M | Sell |
9,300
-36,500
| -80% | -$29.2M | 0.1% | 213 |
|
|
2024
Q1 | $35.6M | Sell |
45,800
-16,900
| -27% | -$12M | 0.41% | 64 |
|
|
2023
Q4 | $36.5M | Buy |
62,700
+14,700
| +31% | +$8.58M | 0.31% | 84 |
|
|
2023
Q3 | $25.8M | Buy |
48,000
+4,200
| +10% | +$2.16M | 0.29% | 99 |
|
|
2023
Q2 | $20.5M | Sell |
43,800
-1,800
| -4% | -$755K | 0.24% | 104 |
|
|
2023
Q1 | $15.7M | Buy |
45,600
+33,200
| +268% | +$11.2M | 0.19% | 142 |
|
|
2022
Q4 | $4.54M | Buy |
12,400
+700
| +6% | +$248K | 0.05% | 367 |
|
|
2022
Q3 | $3.78M | Sell |
11,700
-61,300
| -84% | -$19.4M | 0.04% | 381 |
|
|
2022
Q2 | $23.7M | Sell |
73,000
-3,900
| -5% | -$1.17M | 0.24% | 120 |
|
|
2022
Q1 | $22M | Buy |
76,900
+53,700
| +231% | +$13.8M | 0.21% | 118 |
|
|
2021
Q4 | $6.41M | Buy |
23,200
+16,700
| +257% | +$4.23M | 0.06% | 262 |
|
|
2021
Q3 | $1.5M | Buy |
+6,500
| New | +$1.6M | 0.01% | 581 |
|
|
2018
Q1 | – | Sell |
-25,000
| Closed | -$2.11M | – | 1573 |
|
|
2017
Q4 | $2.11M | Hold |
25,000
| – | – | 0.02% | 501 |
|
|
2017
Q3 | $2.14M | Hold |
25,000
| – | – | 0.02% | 471 |
|
|
2017
Q2 | $2.06M | Buy |
+25,000
| New | +$2.04M | 0.03% | 437 |
|
|
2017
Q1 | – | Sell |
-60,700
| Closed | -$4.46M | – | 1288 |
|
|
2016
Q4 | $4.46M | Sell |
60,700
-8,300
| -12% | -$618K | 0.06% | 252 |
|
|
2016
Q3 | $5.54M | Hold |
69,000
| – | – | 0.08% | 228 |
|
|
2016
Q2 | $5.43M | Buy |
69,000
+68,310
| +9,900% | +$5.14M | 0.08% | 242 |
|
|
2016
Q1 | $568K | Sell |
690
-394
| -36% | -$29.8K | 0.02% | 497 |
|
|
2015
Q4 | $355K | Sell |
1,084
-145
| -12% | -$12K | 0.01% | 728 |
|
|
2015
Q3 | $581K | Buy |
1,229
+182
| +17% | +$15.4K | 0.01% | 644 |
|
|
2015
Q2 | $348K | Buy |
1,047
+26
| +3% | +$1.98K | 0.01% | 759 |
|
|
2015
Q1 | $539K | Buy |
1,021
+743
| +267% | +$52.9K | 0.01% | 590 |
|
|
2014
Q4 | $24K | Buy |
278
+106
| +62% | +$7.16K | ﹤0.01% | 1583 |
|
|
2014
Q3 | $11K | Buy |
172
+57
| +50% | +$3.61K | ﹤0.01% | 1961 |
|
|
2014
Q2 | $11K | Sell |
115
-274
| -70% | -$16.3K | ﹤0.01% | 1840 |
|
|
2014
Q1 | $22K | Sell |
389
-201
| -34% | -$11.2K | ﹤0.01% | 1609 |
|
|
2013
Q4 | $91K | Buy |
590
+121
| +26% | +$6.06K | ﹤0.01% | 1487 |
|
|
2013
Q3 | $102K | Buy |
469
+1
| +0.2% | +$52 | ﹤0.01% | 1450 |
|
|
2013
Q2 | $163K | Buy |
+468
| New | +$25.5K | ﹤0.01% | 1210 |
|
Other funds holding LLY
VCM
VPM
Wolverine Asset Management's LLY Position: Q1 2026 in Review
Wolverine Asset Management opened a new position in Eli Lilly (LLY) in Q1 2026: 7,411 shares worth $6.82M. The stake represents 0.07% of the portfolio and ranks #270 among its holdings. This is a return to the name: Wolverine Asset Management previously reported a position in LLY as recently as Q3 2025.
Wolverine Asset Management first reported a position in LLY in Q2 2013 and has held it in 26 quarters since. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Wolverine Asset Management held 7,411 shares of Eli Lilly worth $6.82M as of Q1 2026.
- Eli Lilly was a new Wolverine Asset Management position in Q1 2026.
- Eli Lilly made up 0.07% of Wolverine Asset Management's portfolio in Q1 2026, its #270 holding.
- Wolverine Asset Management first reported a position in Eli Lilly in Q2 2013 and has held it in 26 quarters since.
- 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.